Page 72 - OHKF_Biotech_EN

5
•
the Mainland market lacks transparency and predictability. It is Bridging regulators of the two cities: A single channel should
74
Policy recommendations for the governments of Hong Kong and Shenzhen
up to the authority to provide adequate support to overcome be set up at the Loop’s one-stop service platform so that a single
these barriers. application can be submitted simultaneously to government
departments of the two cities, making it easier for researchers
and enterprises of the two cities to register research applications
Recommendation 3 Establishing
a one-stop service platform in the Loop to departments of both governments. Apart from the NMPA’s
to provide professional support services GBA Sub-centre for the Approval and Inspection of Medical
Device Technology that have already been established in the
We therefore recommend the establishment of a one-stop Shenzhen park, other national regulators, in particular the
service platform in the Loop to provide biotech transfer National Intellectual Property Administration and the Human
service for Hong Kong and Shenzhen. The platforms may be Genetic Resources Administration of China, can also establish
jointly established by the administrators of the two parks (i.e., the offices in the Loop (see Chapter 6 for details of the
Hong Kong-Shenzhen Innovation and Technology Park Limited recommendation). The single channel can interface with national
and the Futian District Government) through consultations and organisations and corresponding bodies in Hong Kong such as
adopt market-orientated operation with the authorisation of the DH’s Drug Office and the Intellectual Property Department,
government institutions. The platform can foster the sharing of making it easier for applicants to submit applications to relevant
technology industrial policies and developmental dynamics departments of the two governments. Regarding overseas drugs
between the two cities, and also the sharing of public data in entering the Mainland market and Mainland drugs accessing the
commercial, taxation, customs and judicial arenas. It should also overseas market, enterprises can apply to overseas regulators for
address the needs of biotech enterprises through various stages, patent, clinical trials and registration for product launch through
such as investment, registration and production by leveraging on other private professional services providers in the Loop.
resources from Shenzhen, Hong Kong and around the globe.
Specifically, we recommend that the platform should have the
following three major functions (see Figure 21):

74 Hong Kong Trade Development Council Research conducted an online survey from June to July 2020 with 259 start-ups that are headquartered in Hong Kong having been in operation for
less than eight years. 43% of respondents feel that the Mainland and Hong Kong systems are different. 39% are worried about uncertainty in the market environment. 34% feel the GBA
market has insufficient transparency.
70